| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,055,000 ) |
| | 2024 | 2024 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U43AA030689 | Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder. | 001 | 2 | NIH | 7/23/2024 | $1,000,000 |
| | 2024 | 2024 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U43AA030689 | Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder. | 000 | 1 | NIH | 5/7/2024 | $55,000 |
|
| Issue Date FY: 2023 ( Subtotal = $1,000,000 ) |
| | 2023 | 2023 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U43AA030689 | Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder. | 001 | 1 | NIH | 9/26/2023 | -$1,000,000 |
| | 2023 | 2023 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U43AA030689 | Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder. | 001 | 1 | NIH | 9/26/2023 | $1,000,000 |
| | 2023 | 2023 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U43AA030689 | Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder. | 000 | 1 | NIH | 7/31/2023 | $1,000,000 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | R43AA029311 | Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders | 000 | 1 | NIH | 3/17/2022 | $0 |
| | 2022 | 2020 | AMYGDALA NEUROSCIENCES, INC. | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 000 | 2 | NIH | 11/17/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $224,500 ) |
| | 2021 | 2021 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | R43AA029311 | Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders | 000 | 1 | NIH | 9/8/2021 | $224,500 |
|
| Issue Date FY: 2020 ( Subtotal = $450,000 ) |
| | 2020 | 2020 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 003 | 2 | NIH | 9/3/2020 | $450,000 |
| | 2020 | 2019 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 000 | 1 | NIH | 11/12/2019 | -$900,000 |
| | 2020 | 2019 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 001 | 1 | NIH | 11/18/2019 | $900,000 |
| | 2020 | 2019 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 002 | 1 | NIH | 8/21/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $900,000 ) |
| | 2019 | 2019 | AMYGDALA NEUROSCIENCES INC | 509 HALE ST | PALO ALTO | CA | 94301-2210 | SANTA CLARA | USA | U01AA028003 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies | 000 | 1 | NIH | 9/19/2019 | $900,000 |
|
|
